Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F12%3A%230000329" target="_blank" >RIV/00209805:_____/12:#0000329 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/12:33139270

Result on the web

<a href="http://www.spandidos-publications.com/10.3892/ijo.2012.1576" target="_blank" >http://www.spandidos-publications.com/10.3892/ijo.2012.1576</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/ijo.2012.1576" target="_blank" >10.3892/ijo.2012.1576</a>

Result language

angličtina

Original language name

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

Original language description

Trastuzumab is effective in about half of HER2-positive breast cancer patients. The PI3K/Akt signalling pathway plays an important role in the process of primary and secondary resistance to anti-HER2 targeted therapy. We evaluated the relationship between expression, activation and subcellular localization of selected Akt isoforms and response to trastuzumab-based anti-HER2 targeted therapy in patients with HER2-positive metastatic breast cancer. Seventy-four women with verified HER2-positive breast cancer were treated with trastuzumab for metastatic disease. Immunohistochemistry was used to evaluate Akt1, Akt2, pAkt Thr308 and pAkt Ser473 expression. For pAkt, cytoplasmic and nuclear fractions were assessed separately. Even though Akt isoforms were expressed in the majority of tumours, activated Akt (pAkt) was present in the cytoplasm only and not in the nucleus in >20% of tumours, and there was no pAkt at all in another 7-13% of tumours. Patients whose tumours showed strong Akt2 expr

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International journal of oncology

ISSN

1019-6439

e-ISSN

—

Volume of the periodical

41

Issue of the periodical within the volume

4

Country of publishing house

GR - GREECE

Number of pages

9

Pages from-to

1204-1212

UT code for WoS article

—

EID of the result in the Scopus database

—